📰 Deciphera Pharmaceutical News
Page 2 - Deciphera Pharmaceutical News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Deciphera Pharmaceutical. Real-time updates on events, politics, business and more.
January 6, 2023
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH – Get Rating) – Equities researchers at SVB Leerink reduced their FY2026 earnings per share estimates for Deciphera Pharmaceuticals in a note issued to investors on Wednesday, January 4th. SVB Leerink analyst A. Berens now expects that the company will earn $3.38 per share for the year, down from their previous […]
April 19, 2022
Equities analysts expect Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH – Get Rating) to report earnings of ($0.84) per share for the current quarter, according to Zacks Investment Research. Seven analysts have made estimates for Deciphera Pharmaceuticals’ earnings. The lowest EPS estimate is ($1.11) and the highest is ($0.61). Deciphera Pharmaceuticals posted earnings per share of ($1.06) during […]
March 13, 2022
Brokerages predict that Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH – Get Rating) will announce sales of $26.82 million for the current quarter, Zacks reports. Seven analysts have provided estimates for Deciphera Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $22.80 million and the highest estimate coming in at $30.00 million. Deciphera Pharmaceuticals reported sales of […]
December 31, 2021
Blueprint Medicines' (BPMC) Ayvakit, approved to treat PDGFRA Exon 18 mutant gastrointestinal stromal tumors, has seen strong uptake since approval. Other pipeline candidates are also progressing well.
December 22, 2021
– QINLOCK Significantly Reduced the Risk of Disease Progression or Death by 85% and Showed Clinically Meaningful Overall Survival in the INVICTUS Phase 3 Study – ... | December 22, 2021
December 21, 2021
QINLOCK Significantly Reduced the Risk of Disease Progression or Death by 85% and Showed Clinically Meaningful Overall Survival in the INVICTUS Phase 3 Study - Deciphera Pharmaceuticals, Inc.
October 12, 2021
– Seventh Approval Worldwide for QINLOCK and First European Approval – ... | October 12, 2021
October 12, 2021
Seventh Approval Worldwide for QINLOCK and First European Approval - Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a commercial-stage biopharmaceutical company developing innovative medicines
October 12, 2021
Deciphera Announces Approval of QINLOCK® in Switzerland for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor - read this article along with other careers information, tips and advice on BioSpace